Alimera Sciences has announced a positive outcome for its repeat-use procedure for Iluvien, a treatment for diabetic macular edema, in an additional 10 European countries, according to a company press release.
As part of the regulatory process, the company will now enter a national phase to obtain marketing authorization from each of the 10 countries, which include Ireland, the Netherlands, Belgium, Luxembourg, Sweden, Denmark, Finland, Norway, Poland and the Czech Republic.
Iluvien will be indicated for the treatment of vision impairment associated with chronic DME, according to the release.
“Achieving a favorable outcome for Iluvien in these additional EU countries is a significant milestone for Alimera and very encouraging for the many patients throughout Europe with this devastating disease,” Dan Myers, president and CEO of Alimera, said in the press release. “We will continue to work closely with these countries during the national phase to obtain Iluvien marketing authorization in each one.